Bayer HealthCare will invest around EUR 100 million to significantly increase the production capacity of its plant in Beijing, China, in preparation for further demand of its products in the country. The planned capacity expansion is designed to ensure a reliable supply of high-quality products to meet the domestic demand for Bayer HealthCare's products including the company's cardiovascular and anti-diabetes products. The expansion will include logistics areas for fully automated material handling, analytical laboratories, and high-speed packaging lines.
"The expansion of our Beijing site demonstrates our continuous strong commitment to the People's Republic of China," said Dr Olivier Brandicourt, CEO of Bayer HealthCare. "This investment will make Beijing the largest pharmaceuticals packaging site in Bayer HealthCare's global production network."
Bayer is the fourth-largest multinational pharmaceutical company in China, with more than 7,000 employees and production sites in Beijing, Guangzhou, Chengdu and Qidong. The company has already established a center for research and development in Beijing with investments of around EUR 100 million.
For the Bayer Group, Greater China is the largest single market in Asia, accounting for sales of around EUR 3.7 billion in 2013. Currently more than 13,000 people work for the Bayer Group in China, which is also among the major focusses of the company's global investment.
Click here for the complete issue.